
Hinge Bio
Biotechnology company leveraging a next-generation platform for the development of a new class of flexible.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor | €0.0 | round |
investor | €0.0 | round | |
investor | €0.0 | round | |
* | $30.0m | Series A | |
Total Funding | 000k |
Related Content
Hinge Bio operates in the biopharmaceutical industry, focusing on developing advanced therapeutic molecules with enhanced binding capabilities to disease targets. The company serves clients in the healthcare sector, particularly those involved in oncology and immuno-oncology. Hinge Bio's unique technology enables cooperative binding to disease targets, significantly improving the activity and specificity of their therapeutic molecules compared to conventional approaches. This results in new functionalities that offer superior safety and efficacy. The business model revolves around the research and development of these advanced therapeutics, progressing from preclinical to clinical stages, and eventually bringing these products to market. Revenue is generated through the development and commercialization of these therapies, as well as potential partnerships and licensing agreements with larger pharmaceutical companies.
Keywords: biopharmaceutical, oncology, immuno-oncology, cooperative binding, therapeutic molecules, disease targets, safety, efficacy, clinical development, healthcare.